UNSPSC 41131806: Blood cell diluent

In this classification a blood cell diluent is a device used to dilute blood for further testing, such as blood cell counting US FDA regulates Blood cell diluent under 21 CFR 864.8200 and under FDA product code GIF.

UNSPSC 41131806 Blood cell diluent, a Commodity code, encompasses laboratory reagents and supplies supporting hematology and blood chemistry analysis — though recent state and local solicitations tagged under this code actually reflect a broader procurement pattern spanning hemoglobin testing equipment, proficiency testing samples, and ICP-MS consumables for blood lead screening rather than diluent products specifically. State and local buyers under this code include state health departments, university research and clinical laboratories, and specialized testing facilities. Texas Health and Human Services Commission (HHSC) and Department of State Health Services (DSHS) appear as repeat solicitors, procuring both capital equipment for laboratory replacement and ongoing consumable supplies to support pediatric screening and quality assurance functions. Work solicited ranges from one-time equipment acquisitions to recurring supplies contracts with firm and fixed pricing and extension options.

Recent activity centers in Texas and Wisconsin. The Texas HHSC and DSHS issued an Invitation for Bids (IFB) solicitation HHS0017310 posted May 1, 2026, for a D-10 Hemoglobin Testing System with Rack Loader to replace exceeded-life equipment at the South Texas Lab in Harlingen, with a response deadline of May 18, 2026, at 10:30 AM Central Time; historical spend for similar goods ranged $45,050 to $80,000 in fiscal year 2025. The University of Wisconsin-Madison issued a competitive bid solicitation 2026-UWMSN-01287-RFB posted April 3, 2026, for custom-made Hematology/Whole Blood Chemistry Proficiency Testing Samples, with responses due May 5, 2026, through the ShopUW+ portal. The Texas HHSC also issued IFB HHS0017071 posted February 18, 2026, for PerkinElmer ICP-MS consumables and supplies supporting pediatric blood lead analysis, with bids due March 5, 2026, and historical spend of $20,000 to $30,000. All three solicitations involve firm and fixed pricing, best-value evaluation criteria, and no set-aside designations specific to disadvantaged enterprises, though HUB subcontracting plans are encouraged when applicable.